Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biovet JSC's EPS (Basic) for the
three
months ended in Dec. 2016 was лв0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2016 was лв1.76.
Biovet JSC's EPS without NRI for the
three
months ended in Dec. 2016 was лв0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2016 was лв1.76.
During the past 12 months, Biovet JSC's average EPS without NRIGrowth Rate was 58.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 21.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 40.20% per year.
During the past 8 years, Biovet JSC's highest 3-Year average EPS without NRI Growth Rate was 98.60% per year. The lowest was 9.50% per year. And the median was 16.00% per year.
Biovet JSC (LTS:0III) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Biovet JSC Earnings per Share (Diluted) Related Terms
Biovet JSC Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Biovet JSC's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0III vs ADMP, AGRX, BUDZ: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's PE Ratio distribution charts can be found below:
* The bar in red indicates where Biovet JSC's PE Ratio falls into.
Biovet JSC Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Biovet JSC's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2016 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was лв1.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of лв1.76 mean?
Biovet JSC (LTS:0III) has a Earnings per Share (Diluted) of лв1.76 as of Dec. 2016. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Biovet JSC and its competitors.
Is Biovet JSC's Earnings per Share (Diluted) too high?
Biovet JSC's current Earnings per Share (Diluted) is лв1.76.
How does Biovet JSC's Earnings per Share (Diluted) compare to ADMP and AGRX?
Biovet JSC's Earnings per Share (Diluted) of лв1.76 can be compared against companies in the Drug Manufacturers industry. The industry median Earnings per Share (Diluted) is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Biovet JSC and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current Earnings per Share (Diluted) is лв1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current Earnings per Share (Diluted) of лв1.76. The current Earnings per Share (Diluted) is лв1.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current Earnings per Share (Diluted) is лв1.76 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 
